What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Colorectal cancer
The scientist’s investigation covers issues in Internal medicine, Colorectal cancer, Cancer, Oncology and KRAS.
The various areas that Jeffrey A. Meyerhardt examines in his Internal medicine study include Gastroenterology and Surgery.
His work deals with themes such as Prospective cohort study, Disease, Pathology and Cancer research, which intersect with Colorectal cancer.
His studies deal with areas such as Family medicine, Alternative medicine, Proportional hazards model, Physical therapy and Survival analysis as well as Cancer.
Jeffrey A. Meyerhardt combines subjects such as Endocrinology, Regimen, Irinotecan, Fluorouracil and Capecitabine with his study of Oncology.
Jeffrey A. Meyerhardt works mostly in the field of KRAS, limiting it down to topics relating to Cetuximab and, in certain cases, FOLFIRI, Bevacizumab, Metastasis, Predictive value of tests and Salvage therapy.
His most cited work include:
- Nutrition and physical activity guidelines for cancer survivors. (1203 citations)
- Systemic Therapy for Colorectal Cancer (914 citations)
- Physical Activity and Survival After Colorectal Cancer Diagnosis (639 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Colorectal cancer, Oncology, Cancer and Hazard ratio are his primary areas of study.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His KRAS study in the realm of Colorectal cancer connects with subjects such as Microsatellite instability.
The concepts of his Oncology study are interwoven with issues in Bevacizumab, Chemotherapy, Adjuvant therapy, Irinotecan and Oxaliplatin.
His Cancer research incorporates themes from Endocrinology and Pathology.
His Hazard ratio research includes themes of Lower risk, Quartile, Aspirin, Survival analysis and Risk factor.
He most often published in these fields:
- Internal medicine (78.90%)
- Colorectal cancer (66.03%)
- Oncology (51.05%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (78.90%)
- Colorectal cancer (66.03%)
- Oncology (51.05%)
In recent papers he was focusing on the following fields of study:
Jeffrey A. Meyerhardt mainly focuses on Internal medicine, Colorectal cancer, Oncology, Hazard ratio and Cancer.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.
As a part of the same scientific family, Jeffrey A. Meyerhardt mostly works in the field of Colorectal cancer, focusing on Cancer research and, on occasion, Immune system.
His work on Overall survival as part of general Oncology research is frequently linked to In patient, bridging the gap between disciplines.
His biological study spans a wide range of topics, including Incidence, Oxaliplatin, FOLFOX, Aspirin and Survival analysis.
His work carried out in the field of Cancer brings together such families of science as Chemotherapy, Quality of life, Disease, Adipose tissue and Type 2 diabetes.
Between 2019 and 2021, his most popular works were:
- Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. (19 citations)
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (14 citations)
- The Association of Abdominal Adiposity With Mortality in Patients With Stage I-III Colorectal Cancer. (12 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Colorectal cancer, Oncology, Prospective cohort study and Hazard ratio.
His Colorectal cancer study is related to the wider topic of Cancer.
He works mostly in the field of Cancer, limiting it down to topics relating to Adipose tissue and, in certain cases, Proportional hazards model, Radiology, Confidence interval, Underweight and Body mass index, as a part of the same area of interest.
His Oncology research includes elements of Biomarker, Clinical efficacy, Targeted therapy and Disease.
His research in Prospective cohort study intersects with topics in Area under the curve, H&E stain, Immune system and Stromal cell.
His Hazard ratio study incorporates themes from Preoperative care, Surgery, Retrospective cohort study, Waist and Comorbidity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
